Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa (MTBVACN3)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04975178 |
Recruitment Status :
Recruiting
First Posted : July 23, 2021
Last Update Posted : October 10, 2023
|
Sponsor:
Biofabri, S.L
Collaborators:
TuBerculosis Vaccine Initiative
University of Cape Town
Institut Pasteur de Madagascar
Biomedical Research Center EPLS
Universidad de Zaragoza
University of Stellenbosch
University of KwaZulu
Wits Health Consortium (Pty) Ltd
Information provided by (Responsible Party):
Biofabri, S.L
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Recruiting |
---|---|
Estimated Primary Completion Date : | June 2028 |
Estimated Study Completion Date : | September 2029 |
Publications: